PEGylated Thymosin β4 Is a Thiol-Site-Specific Prodrug Treating Myocardial Infarction In Vivo

    March 2026 in “ Bioengineering & Translational Medicine ”
    Haisheng Peng, Yanqun Chai, Chen Gong … Q. Wang
    Studysummary This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. The Overexpression of Tβ4 in the Hair Follicle Tissue of Alpas Cashmere Goats Increases Cashmere Yield and Promotes Hair Follicle Development Animals · 2019
    2. Role of Thymosin Beta 4 in Hair Growth Molecular Genetics and Genomics · 2016
    3. Thymosin Beta 4 Promotes Dermal Healing Vitamins and hormones · 2016